Organic Letters
Letter
Scheme 7. Synthesis of C3−C21 Segment
ACKNOWLEDGMENTS
■
We are grateful for financial support from the Sumitomo
Foundation and the Tokyo Biochemical Research Foundation.
This work was also supported by a Grant-in-Aid for Scientific
Research on Innovative Areas “Frontier Research on Chemical
Communications” (Grant No. 18H04632) and JSPS KAKEN-
HI Grant No. JP17J10228.
REFERENCES
■
(1) (a) Sakuda, S.; Ono, M.; Furihata, K.; Nakayama, J.; Suzuki, A.;
Isogai, A. J. Am. Chem. Soc. 1996, 118, 7855−7856. (b) Ono, M.;
Sakuda, S.; Suzuki, A.; Isogai, A. J. Antibiot. 1997, 50, 111−118.
(c) Ikeda, H.; Matsumori, N.; Ono, M.; Suzuki, A.; Isogai, A.;
Nagasawa, H.; Sakuda, S. J. Org. Chem. 2000, 65, 438−444.
(d) Sakuda, S.; Matsumori, N.; Furihata, K.; Nagasawa, H.
Tetrahedron Lett. 2007, 48, 2527−2531.
(2) (a) Evans, D. A.; Glorius, F.; Burch, J. D. Org. Lett. 2005, 7,
3331−3333. (b) Evans, D. A.; Trenkle, W. C.; Zhang, J.; Burch, J. D.
Org. Lett. 2005, 7, 3335−3338. (c) Robles, O.; McDonald, F. E. Org.
Lett. 2008, 10, 1811−1814. (d) Narute, S. B.; Kiran, N. C.; Ramana,
C. V. Org. Biomol. Chem. 2011, 9, 5469−5475. (e) Narute, S. B.;
Ramana, C. V. Tetrahedron 2013, 69, 1830−1840.
(3) Beiger, J. J. Ph.D. Thesis, Harvard University, 2013.
(4) (a) Shirokawa, S.; Kamiyama, M.; Nakamura, T.; Okada, M.;
Nakazaki, A.; Hosokawa, S.; Kobayashi, S. J. Am. Chem. Soc. 2004,
126, 13604−12605. (b) Hosokawa, S.; Tatsuta, K. Mini-Rev. Org.
Chem. 2008, 5, 1−18. (c) Mukaeda, Y.; Kato, T.; Hosokawa, S. Org.
Lett. 2012, 14, 5298−5301. (d) Tsukada, H.; Mukaeda, Y.;
Hosokawa, S. Org. Lett. 2013, 15, 678−681. (e) Takahashi, Y.;
Otsuka, M.; Harachi, M.; Mukaeda, Y.; Hosokawa, S. Org. Lett. 2014,
16, 4106−4109. (f) Nakamura, T.; Kubota, K.; Ieki, T.; Hosokawa, S.
Org. Lett. 2016, 18, 132−135.
(5) (a) Hosokawa, S. Acc. Chem. Res. 2018, 51, 1301−1314.
(b) Hosokawa, S. Yuki Gosei Kagaku Kyokaishi 2017, 75, 831−849.
(6) Murakoshi, S.; Hosokawa, S. Synlett 2015, 26, 2437−2441.
(7) Schultz, H. S.; Freyermuth, H. B.; Buc, S. R. J. Org. Chem. 1963,
28, 1140−1142.
reduction of the p-methoxybenzylidene acetal17 afforded the
primary alcohol 37 in good yield. The resulting alcohol 37 was
subjected to Dess−Martin oxidation to give C3−C21 segment
(3).
In conclusion, a stereoselective and convergent synthesis of
the C3−C21 segment of aflastatin A has been achieved. All
segments were prepared in six to eight steps using the remote
asymmetric reactions including the allylation reaction (C3−C8
segment) and the vinylogous Mukaiyama aldol reactions (C9−
C15 and C16−C21 segments). Therefore, the C3−C21
segment of aflastatin A was synthesized in 17 steps of longest
linear sequence from vinylketene silyl N,O-acetal 9.
(8) Matsui, R.; Seto, K.; Sato, Y.; Suzuki, T.; Nakazaki, A.;
Kobayashi, S. Angew. Chem., Int. Ed. 2011, 50, 680−683.
(9) Hasan, I.; Kishi, Y. Tetrahedron Lett. 1980, 21, 4229−4232.
(10) (a) Peterson, I.; Channon, J. A. Tetrahedron Lett. 1992, 33,
797−800. (b) Nakata, M.; Osumi, T.; Ueno, A.; Kimura, T.; Tamai,
T.; Tatsuta, K. Bull. Chem. Soc. Jpn. 1992, 65, 2974−2991. (c) Evans,
D. A.; Ratz, A. M.; Huff, B. E.; Sheppard, G. S. J. Am. Chem. Soc. 1995,
117, 3448−3467.
(11) For determination of the stereochemistry of compounds in this
(12) Jung, M. E.; D’amico, D. C. J. Am. Chem. Soc. 1993, 115,
ASSOCIATED CONTENT
* Supporting Information
The Supporting Information is available free of charge on the
12208−12209.
■
(13) Blakemore, P. R.; Cole, W. J.; Kocienski, P. J.; Morley, A.
Synlett 1998, 1998, 26−28.
S
(14) Removal of the trimethylsilyl group at the C11 position was
found to be critical to promote the Sharpless asymmetric epoxidation.
(15) Ohashi, T.; Hosokawa, S. Org. Lett. 2018, 20, 3021−3024.
(16) Narasaka, K.; Pai, F. C. Tetrahedron 1984, 40, 2233−2238.
(17) Takano, S.; Akiyama, M.; Sato, S.; Ogasawara, K. Chem. Lett.
1983, 12, 1593−1596.
Experimental procedures, spectral data of compounds,
1H and 13C NMR spectra, and structural determination
AUTHOR INFORMATION
■
Corresponding Author
ORCID
Notes
The authors declare no competing financial interest.
D
Org. Lett. XXXX, XXX, XXX−XXX